Literature DB >> 16467334

Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

R Phillips1, C Horsfield, S Kuijper, S F Sarfo, J Obeng-Baah, S Etuaful, B Nyamekye, P Awuah, K M Nyarko, F Osei-Sarpong, S Lucas, A H J Kolk, M Wansbrough-Jones.   

Abstract

Mycobacterium ulcerans disease (Buruli ulcer) is a skin-ulcerating infection common in some parts of the tropics. We have investigated cytokine secretion after stimulation of whole blood from Buruli ulcer (BU) patients in a region of endemicity in Ghana with M. ulcerans sonicate or culture filtrate antigens to investigate the development of the response over time and its specificity by comparison with the response to Mycobacterium tuberculosis sonicate in human immunodeficiency virus-negative tuberculosis patients. Significant gamma interferon (IFN-gamma) production in response to whole-blood stimulation with M. ulcerans sonicate was detected in patients with ulcers, which was higher than that in patients with nodules but similar to subjects with healed BU. The mean IFN-gamma response in household contacts of BU patients was not significantly different from that in healthy control subjects from an area of nonendemicity. Results in patients with untreated, smear-positive pulmonary tuberculosis and tuberculosis patients on treatment for more than 2 weeks showed that BU patients responded better to M. ulcerans antigens than tuberculosis patients. In contrast, interleukin-10 results were higher in patients with active M. ulcerans disease than in those with healed lesions, but the pattern of response was similar to that seen in tuberculosis. A similar pattern of cytokine secretion was found using M. tuberculosis sonicate as an antigen. Neither of the two culture filtrate antigens of M. ulcerans appeared to be more specific than M. ulcerans sonicate. In the early stages of M. ulcerans disease there was a mixed Th1 and Th2 cytokine response, but the Th1 response emerged as the dominant type.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467334      PMCID: PMC1391935          DOI: 10.1128/CVI.13.2.253-257.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts.

Authors:  Inger Brock; Karin Weldingh; Troels Lillebaek; Frank Follmann; Peter Andersen
Journal:  Am J Respir Crit Care Med       Date:  2004-04-15       Impact factor: 21.405

2.  Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.

Authors:  G H Mazurek; P A LoBue; C L Daley; J Bernardo; A A Lardizabal; W R Bishai; M F Iademarco; J S Rothel
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

Review 3.  Protection against tuberculosis: cytokines, T cells, and macrophages.

Authors:  S H E Kaufmann
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

4.  Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10.

Authors:  I Brock; M E Munk; A Kok-Jensen; P Andersen
Journal:  Int J Tuberc Lung Dis       Date:  2001-05       Impact factor: 2.373

5.  Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts.

Authors:  Travis M Gooding; Paul D R Johnson; May Smith; Andrew S Kemp; Roy M Robins-Browne
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

6.  Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens.

Authors:  Toru Mori; Mitsunori Sakatani; Fumio Yamagishi; Tetsuya Takashima; Yoshiko Kawabe; Keiji Nagao; Eriko Shigeto; Nobuyuki Harada; Satoshi Mitarai; Masaji Okada; Katsuhiro Suzuki; Yoshikazu Inoue; Kazunari Tsuyuguchi; Yuka Sasaki; Gerald H Mazurek; Izuo Tsuyuguchi
Journal:  Am J Respir Crit Care Med       Date:  2004-04-01       Impact factor: 21.405

7.  Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection.

Authors:  Anna Fietta; Federica Meloni; Alessandro Cascina; Monica Morosini; Carlo Marena; Panaiota Troupioti; Patrizia Mangiarotti; Lucio Casali
Journal:  Am J Infect Control       Date:  2003-10       Impact factor: 2.918

8.  Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test.

Authors:  Pernille Ravn; Martin E Munk; Ase Bengaard Andersen; Bettina Lundgren; Lars N Nielsen; Troels Lillebaek; Inge J Soerensen; Peter Andersen; Karin Weldingh
Journal:  Scand J Infect Dis       Date:  2004

9.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Authors:  Ghislaine Prévot; Eliane Bourreau; Herve Pascalis; Roger Pradinaud; Audrey Tanghe; Kris Huygen; Pascal Launois
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 10.  Dynamics of cytokine generation in patients with active pulmonary tuberculosis.

Authors:  Eun-Kyeong Jo; Jeong-Kyu Park; Hazel M Dockrell
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

View more
  14 in total

1.  Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Authors:  Egídio Torrado; Alexandra G Fraga; António G Castro; Pieter Stragier; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 2.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

3.  Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity.

Authors:  Alvar Grönberg; Louise Zettergren; Kerstin Bergh; Mona Ståhle; Johan Heilborn; Kristian Angeby; Pamela L Small; Hannah Akuffo; Sven Britton
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

4.  Effects of Chinese herbal recipes on immunity in immunosuppressive mice.

Authors:  Yongzhan Bao; Cui Jing; Wanyu Shi
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-07-01

5.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

6.  Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

Authors:  F S Sarfo; R O Phillips; E Ampadu; F Sarpong; E Adentwe; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

7.  Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.

Authors:  R Phillips; C Horsfield; J Mangan; K Laing; S Etuaful; P Awuah; K Nyarko; F Osei-Sarpong; P Butcher; S Lucas; M Wansbrough-Jones
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

8.  Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice.

Authors:  Raphael Bieri; Miriam Bolz; Marie-Thérèse Ruf; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2016-02-10

9.  Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.

Authors:  Hui Hong; Emmanuelle Coutanceau; Marion Leclerc; Laxmee Caleechurn; Peter F Leadlay; Caroline Demangel
Journal:  PLoS Negl Trop Dis       Date:  2008-10-22

Review 10.  Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria.

Authors:  Hui Hong; Caroline Demangel; Sacha J Pidot; Peter F Leadlay; Tim Stinear
Journal:  Nat Prod Rep       Date:  2008-04-17       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.